| Abstract: | Recently there have been numerous advances in understanding the genetic basis of cancer which have resultedin more appropriate treatments. In this paper we describe the experience of the Burzynski Clinic, involved intreatment of numerous patients based on personalized approach using novel combinations for difficult-to-treatmalignancies, with gynecological cancers. This retrospective study was conducted by extracting data fromBurzynski Clinic’s medical records and comprehensive review. Among the advanced refractory ovarian cancerscases (N=33), an objective response (OR) was found in 42.4%. We anticipate that with improved technology andnovel therapeutics this rate will increase and adverse events will be reduced. |
